Cleo Diagnostics (ASX:COV) Notes Receivable: A$0.00 Mil (As of Dec. 2025)


ASX:COV Cleo Diagnostics Ltd ASX:COV
17 GF Score
Price A$0.51
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Notes Receivable?

Cleo Diagnostics ASX:COV +1.00% 17 Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Cleo Diagnostics's Notes Receivable for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Cleo Diagnostics Notes Receivable Related Terms

Cleo Diagnostics Notes Receivable Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Notes Receivable Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
Notes Receivable
0.00 0.00 0.00

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ASX:COV
17GF Score
Cleo Diagnostics Ltd ASX:COV
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of A$0.00 Mil mean?
Cleo Diagnostics (ASX:COV) has a Notes Receivable of A$0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Notes Receivable too high?
Cleo Diagnostics' current Notes Receivable is A$0.00 Mil. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Notes Receivable compare to ABT and SYK?
Cleo Diagnostics' Notes Receivable of A$0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Notes Receivable is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Notes Receivable of A$0.00 Mil. The current Notes Receivable is A$0.00 Mil. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Notes Receivable is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score

Get the complete analysis for ASX:COV

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.51
Price